The regulatory and reimbursement fight continued on multiple fronts: the U.S. Department of Justice weighed in favor of pharma positions in a yearslong 340B contract pharmacy dispute, adding momentum to drugmakers seeking expanded leverage over federal discount rules. Separately, 131 hospitals sued HHS and CMS over alleged underpayment tied to how Medicare disproportionate share hospital (DSH) payments are calculated. The hospital lawsuit targets the CMS policy hospitals say improperly reduces DSH payments by counting patient days in a way that disadvantages safety-net facilities. For pharma, the 340B dispute shapes how discounts are operationalized through contracted pharmacies. Taken together, the actions signal sustained pressure on both sides of healthcare financing—discount access and safety-net funding—likely affecting payer strategy, contracting, and patient access for high-cost therapies.